Clinical experience and treatment considerations with vesicular monoamine transport 2 inhibitors
{{output}}
Vesicular monoamine transporter 2 inhibitors (VMAT2i) are currently Food and Drug Administration-approved for the treatment of Huntington disease chorea and tardive dyskinesia. Additionally, they are often used for other hyperkinetic movement disorders in clin... ...
